Ocrevus减少了多种MS病人的残疾进展,在现实世界数据中,其他治疗效果优于其他治疗,新的药物芬内布鲁蒂尼布显示出强劲的结果。 Ocrevus reduced disability progression in diverse MS patients and outperformed other treatments in real-world data, with new drug fenebrutinib showing strong results.

Roche在2025年ECTRIMS大会上提交了新数据,显示COREEVUS(ocrelizumab)有效减少了各种MS患者的残疾进展,包括具有高级初级渐进MS、孕妇或哺乳期妇女以及儿童。 Roche presented new data at the 2025 ECTRIMS Congress showing OCREVUS (ocrelizumab) effectively reduces disability progression in diverse MS patients, including those with advanced primary progressive MS, pregnant or breastfeeding women, and children. 它证明两年来持续复发和损伤抑制,其安全性与静脉注射剂量相当。 It demonstrated sustained relapse and lesion suppression over two years, with safety comparable to intravenous dosing. 来自三个大登记册的真实世界数据发现,在减少复发方面,奥克里利祖马布比其他几个理疗疗法更有效,特别是在有主动疾病或先前治疗失败的病人中。 Real-world data from three large registries found ocrelizumab more effective than several other MS therapies at reducing relapses, particularly in patients with active disease or prior treatment failure. 此外,BTK Fenebrutinib实验性BTK抑制剂第二阶段的结果显示,在96周内几乎完全抑制了疾病活动。 Additionally, phase II results for the experimental BTK inhibitor fenebrutinib showed near-complete suppression of disease activity through 96 weeks. 这些调查结果强化了Ocrelizumab作为多种MS类型关键治疗手段的作用,并突出了在管理这一疾病方面正在取得的进展。 These findings reinforce ocrelizumab’s role as a key treatment for multiple MS types and highlight ongoing progress in managing the disease.